Last updated: September 2, 2026
Gadopiclenol is a high-relaxivity, macrocyclic gadolinium-based contrast agent positioned to reduce gadolinium exposure during magnetic resonance imaging. Its commercial outlook is favorable but incremental. The drug competes against established macrocyclic agents, including gadobutrol, gadoterate meglumine, and gadoteridol, while its financial performance remains difficult to isolate because Guerbet and Bracco report contrast-media revenue at broader portfolio levels.
The principal commercial advantages are a 0.05 mmol/kg dose, high relaxivity, and potential reduction in gadolinium administered per examination. The principal risks are established hospital formularies, procurement-driven pricing, generic competition in older gadolinium agents, and limited clinical evidence that lower gadolinium exposure alone produces a material change in imaging-center economics.
What is gadopiclenol and how is it marketed?
Gadopiclenol is a macrocyclic gadolinium complex used for contrast-enhanced MRI of the central nervous system and body. It is administered intravenously and has a recommended dose of 0.05 mmol/kg, approximately half the gadolinium dose used by several competing extracellular agents.
Two branded products are associated with gadopiclenol:
| Product |
Company |
Primary market |
FDA status |
| Elucirem |
Guerbet |
United States |
Approved September 2022 |
| Vueway |
Bracco |
United States and international markets |
Approved in the United States in 2022 |
The FDA approved Elucirem for adults and pediatric patients aged 2 years and older for contrast-enhanced MRI of the central nervous system and body. The Vueway label covers contrast-enhanced MRI in adults and pediatric patients aged 2 years and older, including CNS, body, and vascular applications depending on jurisdiction and labeling [1,2].
Gadopiclenol was developed to produce higher signal enhancement per mole of gadolinium. That property supports a lower administered dose, but it does not eliminate the need for renal-risk screening or institutional controls governing gadolinium-based contrast agents.
How large is the gadopiclenol market?
Gadopiclenol competes in the broader global market for gadolinium-based contrast agents, which is substantially larger than the product itself. Public market-research estimates for the total GBCA market vary widely because they use different geographic scopes, hospital purchasing data, and definitions of contrast media.
The addressable market includes:
- Routine brain MRI.
- Spine and musculoskeletal imaging.
- Abdominal and pelvic MRI.
- Vascular imaging.
- Oncology imaging.
- Pediatric MRI.
- Imaging centers and hospitals that use macrocyclic agents as first-line products.
Gadopiclenol’s near-term market share is likely to remain a minority position because gadobutrol, gadoterate, and gadoteridol already have established commercial relationships with radiology departments. Adoption depends less on physician awareness than on formulary approval, supply reliability, price, and the ability of sales teams to demonstrate equivalent or superior image quality.
How does gadopiclenol compare with competing MRI contrast agents?
| Agent |
Common brand |
Structural class |
Typical gadolinium dose |
Market position |
| Gadopiclenol |
Elucirem, Vueway |
Macrocyclic |
0.05 mmol/kg |
Newer high-relaxivity entrant |
| Gadobutrol |
Gadavist, Gadovist |
Macrocyclic |
0.1 mmol/kg |
Established global product |
| Gadoterate meglumine |
Dotarem, Clariscan |
Macrocyclic |
0.1 mmol/kg |
Broad hospital use; generic competition |
| Gadoteridol |
ProHance |
Macrocyclic |
0.1 mmol/kg |
Established CNS and body MRI use |
| Gadoxetate disodium |
Eovist, Primovist |
Linear hepatobiliary |
0.025 mmol/kg |
Liver-specific differentiation |
| Gadobenate dimeglumine |
MultiHance |
Linear |
0.1 mmol/kg |
Declining strategic importance in some markets |
Gadopiclenol’s strongest differentiation is dose efficiency rather than a wholly new imaging indication. The agent may be attractive for institutions seeking to reduce cumulative gadolinium exposure while maintaining image quality. That proposition is strongest in repeated-imaging populations, pediatric patients, oncology surveillance, and patients with heightened institutional concern about gadolinium retention.
What FDA exclusivity protects gadopiclenol?
Elucirem received FDA approval on September 21, 2022. As the first approved product containing gadopiclenol as the active moiety, it received five-year new chemical entity exclusivity, subject to the applicable FDA rules governing subsequent applications and patent challenges. The core NCE exclusivity period therefore runs to September 2027.
The regulatory timeline is:
| Event |
Date |
| FDA approval of Elucirem |
September 21, 2022 |
| Expected end of five-year NCE exclusivity |
September 2027 |
| FDA approval of Vueway |
2022 |
| Earliest practical ANDA challenge window for core exclusivity |
After NCE restrictions, subject to listed patents |
Vueway’s approval does not restart five-year NCE exclusivity for gadopiclenol. A later approval may receive application-specific exclusivity for new clinical investigations or other qualifying changes, but that period does not recreate first-applicant NCE protection for the active moiety.
What patents protect gadopiclenol?
Gadopiclenol is protected by a layered intellectual-property strategy rather than by regulatory exclusivity alone. The relevant categories include:
- Composition-of-matter protection for the gadopiclenol molecule and related chelates.
- Pharmaceutical-composition patents covering injectable formulations.
- Use patents covering contrast-enhanced MRI applications.
- Manufacturing patents covering synthesis, purification, complexation, and control of impurities.
- Potential process and formulation claims covering concentration, pH, excipients, and container systems.
Patent protection is split between the originator developers and commercial partners. Guerbet is the principal innovator associated with Elucirem, while Bracco commercializes Vueway. Licensing, supply, and territorial rights can affect economic control even where a company is not the original patent owner.
The commercial patent question is the earliest date on which an ANDA applicant can launch without infringing an unexpired Orange Book-listed patent. That date can differ from the expiration of the composition patent because formulation, use, and manufacturing patents may extend the effective barrier.
What is the Orange Book status of gadopiclenol?
FDA Orange Book records are the controlling source for listed patents and regulatory exclusivity. Elucirem and Vueway are prescription injectable products approved under separate NDAs. Their patent listings and exclusivity records must be assessed by NDA rather than by active ingredient alone.
The key legal distinction is that an ANDA applicant can submit a Paragraph IV certification against a listed patent before patent expiry. The reference sponsor may then bring patent litigation, triggering a potential 30-month stay of approval under the Hatch-Waxman framework, subject to statutory conditions and FDA administration [3].
Publicly visible commercial risk is therefore concentrated in the period from the end of NCE exclusivity in 2027 through the expiration of the last enforceable listed patent. A precise launch date cannot be inferred from NCE expiry alone.
When does gadopiclenol lose exclusivity?
The first meaningful loss of exclusivity date is September 2027, when Elucirem’s five-year NCE exclusivity is expected to expire. Patent protection may continue beyond that date.
| Protection type |
Expected timing or status |
| Elucirem NCE exclusivity |
Through September 2027 |
| Vueway’s independent approval |
Does not reset NCE protection |
| Listed formulation or use patents |
May extend beyond 2027 |
| Manufacturing patents |
May create supply or process barriers |
| ANDA Paragraph IV activity |
Possible before patent expiry |
| Commercial generic entry |
Dependent on litigation, patent outcomes, and FDA approval |
Pediatric exclusivity could extend certain listed exclusivity periods by six months if the sponsor completed qualifying FDA-requested pediatric studies. No public conclusion should be drawn about a six-month extension without reviewing the applicable FDA exclusivity record and pediatric-study determinations.
Which companies are challenging gadopiclenol?
There is no widely reported, commercially significant Paragraph IV litigation campaign against gadopiclenol comparable to the litigation surrounding major small-molecule blockbusters. That position may change as the 2027 NCE expiry approaches and the market reaches sufficient sales scale to justify generic development.
Likely sources of competitive pressure include:
- Generic injectable manufacturers with existing sterile manufacturing infrastructure.
- Established GBCA suppliers seeking portfolio expansion.
- Contract manufacturers that already produce gadolinium-based products.
- Hospital systems that negotiate direct supply contracts.
- Biosimilar developers are not relevant because gadopiclenol is a chemically synthesized small molecule, not a biologic.
The technical barrier is moderate. Production requires control of chelation chemistry, residual free gadolinium, endotoxins, particulates, sterility, stability, and container closure. Those requirements are meaningful but familiar to manufacturers already producing injectable GBCAs.
How strong is the gadopiclenol patent estate?
The patent estate is commercially meaningful but less defensible than the estate surrounding a novel therapeutic molecule with multiple disease indications. Gadopiclenol has one principal imaging use and competes with several approved agents that can be substituted at the formulary level.
Patent strength is highest where claims cover:
- The active chelate itself.
- A narrow and reproducible manufacturing process.
- Critical impurity controls.
- Stable injectable compositions.
- Specific dose or imaging protocols supported by clinical data.
Method-of-use patents are more vulnerable to design-around and physician-use challenges than composition patents. Manufacturing patents can complicate generic entry but may not prevent a competitor from using a non-infringing process. The commercial durability of gadopiclenol therefore depends on the interaction of patent breadth, Orange Book listings, regulatory exclusivity, and the willingness of generic manufacturers to accept litigation risk.
What is the financial trajectory for gadopiclenol?
No public company reports gadopiclenol revenue as a standalone line item. Guerbet reports consolidated or segment-level revenue, while Bracco is privately held and does not provide the same level of public product disclosure as a listed pharmaceutical company.
The financial trajectory is best characterized in phases:
2022-2023: Launch and formulary establishment
The initial period was driven by regulatory approvals, distribution, medical education, and hospital contracting. Revenue was likely modest relative to total GBCA sales because new agents typically require conversion from entrenched products.
2024-2026: Portfolio expansion
This is the main scaling period. Growth depends on:
- Inclusion in hospital formularies.
- Head-to-head imaging experience.
- Adoption in high-volume MRI centers.
- Supply and vial availability.
- Reimbursement treatment.
- Price relative to gadobutrol and gadoterate.
- Evidence supporting reduced-dose use.
Gadopiclenol can grow faster than the overall MRI market if it takes share from established agents. It can still deliver attractive revenue growth with limited category expansion because MRI procedure volumes are relatively mature in developed markets.
2027 onward: Pre-generic erosion risk
The end of NCE exclusivity creates a clear valuation inflection point. If patent litigation delays generic approval, branded revenue could continue growing or remain stable. If multiple ANDA applicants obtain approval near the end of the patent period, price erosion could be rapid because injectable contrast agents are purchased through institutional tenders and group purchasing organizations.
A practical scenario framework is:
| Scenario |
Commercial outcome |
Financial effect |
| Upside |
Broad formulary adoption and sustained premium pricing |
Strong growth through the late 2020s |
| Base case |
Gradual share capture with price pressure |
Moderate growth, followed by erosion after generic entry |
| Downside |
Limited differentiation and early competitive pricing |
Low share, weak margin expansion, rapid post-exclusivity decline |
What revenue exposure do Guerbet and Bracco have?
Gadopiclenol is strategically important because it gives both companies a newer macrocyclic product with a differentiated dose profile. It is unlikely to represent the majority of either company’s total revenue during the initial launch cycle.
Guerbet has a broader portfolio that includes established MRI and CT contrast products, interventional imaging products, and imaging technologies. Its financial exposure to Elucirem is therefore meaningful at the growth-product level but not equivalent to dependence on a single blockbuster.
Bracco has a diversified diagnostic-imaging portfolio and private ownership structure. Vueway can support portfolio retention and premiumization in MRI contrast media, but Bracco does not publicly disclose product-level revenue sufficient to calculate sales contribution or margin.
Investors should avoid treating total Guerbet or Bracco contrast-media revenue as gadopiclenol revenue. That would overstate product-specific performance.
What licensing and supply relationships affect gadopiclenol?
The commercial structure involves originator development, regional regulatory rights, and manufacturing or distribution arrangements. Guerbet is associated with the development and Elucirem franchise, while Bracco markets Vueway. These parallel branded products create an unusual market structure for one active ingredient.
The implications are:
- Two branded products can compete before generic entry.
- Hospital buyers may negotiate one brand against the other.
- Patent ownership and marketing rights may be separated.
- Manufacturing scale and supply reliability can influence market share.
- A generic entrant could face multiple branded incumbents rather than one originator.
The presence of two branded products may accelerate physician familiarity with gadopiclenol but can also limit pricing power if the brands compete directly.
What generic launch risks exist for gadopiclenol?
Generic entry is plausible after the NCE period, but timing depends on the Orange Book patent portfolio and litigation. The most likely launch pattern is:
- Paragraph IV filings before the end of patent protection.
- Patent litigation by one or both branded sponsors.
- Potential 30-month approval stay.
- One or more first generic approvals.
- Rapid institutional price competition.
- Subsequent erosion as additional sterile-injectable suppliers enter.
Biosimilar risk is not applicable. The relevant regulatory pathway is an ANDA for a chemically equivalent injectable product, not a 351(k) biosimilar application.
How does gadopiclenol compare with the broader MRI contrast market?
Gadopiclenol has stronger differentiation than another standard-dose macrocyclic GBCA because its low-dose positioning is visible to radiologists, procurement teams, and institutional safety committees. It has weaker differentiation than a contrast agent tied to a unique organ-specific indication, such as gadoxetate for hepatobiliary imaging.
Its commercial ceiling will be determined by whether lower gadolinium exposure changes purchasing behavior. If hospitals view gadopiclenol as clinically interchangeable with existing macrocyclic agents, price becomes the primary decision variable. If the reduced-dose profile gains support in repeated imaging and pediatric use, the product can sustain a premium and delay substitution.
Key Takeaways
- Gadopiclenol is a high-relaxivity macrocyclic GBCA marketed as Elucirem by Guerbet and Vueway by Bracco.
- FDA approval began in 2022, with Elucirem’s five-year NCE exclusivity expected to run through September 2027.
- The product’s main differentiation is a 0.05 mmol/kg dose and lower administered gadolinium exposure.
- Revenue is not publicly disclosed at the product level by Guerbet or Bracco.
- Adoption should be gradual because hospitals already use established macrocyclic agents.
- The patent estate may extend beyond NCE expiry through composition, formulation, use, and manufacturing claims.
- Generic competition is more relevant than biosimilar competition.
- The most important valuation issue is whether gadopiclenol achieves durable formulary share before Paragraph IV activity begins.
FAQs
Is gadopiclenol a macrocyclic gadolinium contrast agent?
Yes. Gadopiclenol is a macrocyclic gadolinium-based contrast agent with high relaxivity and a recommended dose of 0.05 mmol/kg.
Is gadopiclenol safer than gadobutrol?
Both are macrocyclic agents designed for high kinetic stability. Gadopiclenol reduces the administered gadolinium dose, but lower dose does not remove all safety considerations associated with gadolinium contrast agents.
Is gadopiclenol available as a generic?
No broadly marketed generic gadopiclenol has been established in the United States based on the regulatory and commercial record through the current launch period. Generic entry is most relevant after the September 2027 NCE-exclusivity milestone and resolution of listed patents.
Who owns Elucirem?
Elucirem is associated with Guerbet, which developed and markets the product in the United States.
Who manufactures Vueway?
Vueway is associated with Bracco Diagnostics and is marketed as a gadopiclenol product distinct from Guerbet’s Elucirem franchise.
References
-
U.S. Food and Drug Administration. (2022). Elucirem (gadopiclenol) injection prescribing information. FDA.
-
U.S. Food and Drug Administration. (2022). Vueway (gadopiclenol) injection prescribing information. FDA.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
Guerbet. (2024). Universal registration document and annual financial report. Guerbet.
-
Bracco. (2023). Vueway: Gadopiclenol injection product information. Bracco Diagnostics.
